Keyphrases
Pediatric Patients
71%
Acute Lymphoblastic Leukemia
67%
Pediatric
62%
Pediatric Leukemia
52%
Netherlands
50%
Acute Myeloid Leukemia
45%
Pharmacokinetics
41%
Population Pharmacokinetics
30%
Dutch
30%
Leukemia
28%
Relapsed or Refractory
26%
Pediatric Oncology
24%
Improved Survival
23%
Newly Diagnosed
23%
Young Adolescents
22%
Leukemia Patients
22%
Phase II Study
21%
Older Adults
21%
Confidence Interval
20%
Children with Cancer
19%
Gemtuzumab Ozogamicin
19%
KMT2A
19%
Preadolescent children
18%
Neuroblastoma
18%
Hematopoietic Stem Cells
17%
Pediatric Acute Lymphoblastic Leukemia
17%
Down Syndrome
16%
Hematopoietic Stem Cell Transplantation
15%
Overall Survival
15%
Average Annual Percentage Change
15%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
14%
Oncology
14%
Pediatric Cancer
13%
Acute Leukemia
13%
Population-based Study
13%
High-risk Neuroblastoma
13%
5-year Survival
13%
Relapsed or Refractory Acute Myeloid Leukemia
13%
Precision Oncology
13%
Cancer-related Fatigue
13%
Aprepitant
13%
Neonate
13%
Clinical Trials
12%
Clinical Outcomes
12%
Minimal Residual Disease
12%
Treatment Response
12%
Childhood Acute Lymphoblastic Leukemia
12%
Bone Marrow
11%
T Cells
11%
BCP-ALL
11%
Cancer Registry
10%
Hodgkin Lymphoma
10%
Clinically Significant
10%
Working Diagnosis
10%
Classical Hodgkin Lymphoma
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Event-free Survival
10%
Chimeric Antigen Receptor T-cell Therapy
10%
Sleep Problems
10%
CD22
10%
Young Cancer Patients
9%
Paediatric Strategy Forum
9%
Improved Outcomes
9%
Non-Hodgkin Lymphoma
9%
Solid Tumors
9%
Chronic Myeloid Leukemia
9%
Incidence Trends
9%
European Medicines Agency
9%
Pediatric AML
9%
Myelodysplastic Syndrome
9%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
9%
Risk Factors
8%
Innovative Therapies
8%
Targeted Therapy
8%
Drug Development
8%
Clofarabine
8%
Sleep-wake Rhythm
8%
Nilotinib
8%
Treatment Effect
8%
Medullary Thyroid Cancer
8%
Targeted Treatment
8%
Medicinal Product Development
8%
Activation-regulated Chemokine
8%
Thymus
8%
Differentiated Thyroid Cancer
8%
Trisomy 21
8%
Azacitidine
8%
P53 Pathway
8%
Increased Incidence
8%
Human Plasma
8%
Genome Analysis
8%
In Cancer
8%
Maintenance Therapy
8%
Chemotherapy
8%
New Agents
8%
Survival Rate
8%
CD123
7%
High Risk
7%
Pediatric Tumors
7%
RNA Sequencing (RNA-seq)
7%
Medicine and Dentistry
Pediatrics
100%
Acute Lymphoblastic Leukemia
70%
Adolescence
57%
Acute Myeloid Leukemia
50%
Pediatric Acute Myeloid Leukemia
43%
Malignant Neoplasm
39%
Pediatrics Patient
34%
Disease
32%
Ganglioneuroblastoma
31%
Childhood Cancer
29%
Oncology
26%
Overall Survival
24%
Neoplasm
24%
Immunotherapy
22%
Leukemia
19%
Acute Myelogenous Leukemia
18%
Inotuzumab Ozogamicin
18%
Cancer
15%
Down Syndrome
15%
Pediatric Cancer
14%
Minimal Residual Disease
14%
Targeted Therapy
14%
Dexamethasone
13%
Clinical Trial
12%
Hodgkin's Lymphoma
11%
Somatics
11%
Maintenance Therapy
11%
Cancer Registry
10%
Hematopoietic Cell
10%
Hematopoietic Stem Cell Transplantation
10%
Thymus and Activation Regulated Chemokine
10%
Classical Hodgkin Lymphoma
10%
Acute Leukemia
10%
Treatment Response
10%
Event Free Survival
10%
Chemotherapy
9%
Side Effect
9%
Kidney Tumour
9%
Survival Rate
9%
Leukemia in Children
9%
Medicine
9%
Personalized Medicine
9%
Wilms' Tumor
8%
Randomized Controlled Trial
8%
Cancer-Related Fatigue
8%
Sleep Waking Cycle
8%
Retrospective Study
8%
Diagnosis
8%
Progression Free Survival
7%
Leukemia Cell
7%
Central Nervous System Tumor
7%
Anaplastic Lymphoma Kinase
7%
T Cell
7%
B Cell
6%
Non-Hodgkin Lymphoma
6%
Lymphoblastic Lymphoma
6%
Chimeric Antigen Receptor T-Cell
6%
Experimental Therapy
6%
Mortality Rate
6%
Precursor
6%
Pilocytic Astrocytoma
5%
Chimeric Antigen Receptor T-Cell Immunotherapy
5%
Cancer Susceptibility
5%
Fusion Gene
5%
RNA Sequence
5%
Immunophenotyping
5%
Molecular Profiling
5%
Immunity
5%
Drug Megadose
5%
In Vitro
5%
Solid Malignant Neoplasm
5%
Tumor Microenvironment
5%
Phase II Trials
5%
Chronic Myelogenous Leukemia
5%
Patient with Leukemia
5%
Arm
5%
Calicheamicin
5%